Oncotherapeutics, an oncology CRO has added David Donahue as its new Senior Director of Clinical Operations. Formerly Director of Clinical Operations at Arena Pharmaceuticals in San Diego, California, Donahue is a veteran drug development professional with more than twenty years experience directing, designing, implementing, monitoring, and managing clinical trials.
CEO of Oncotherapeutics, James R. Berenson, MD states, “Mr. Donahue has worked in a variety of therapeutic areas in the pharmaceutical and CRO arena and has broad experience in conducting Phase I-III clinical trials in North America, Europe, and Asia. Due to our progressive growth, we see a great need for someone with Dave’s specific skill set and background and feel he will make a tremendous contribution to increasing the success of Oncotherapeutics.”
David Donahue started his career as a Biologist with Syntex Research now Roche Biosciences. During his 10+ years with the company, he held progressive roles as Biologist I/II/III, CRA and Clinical Research Manager. He then transitioned to Quintiles and later was instrumental in setting up the San Diego offices for SCIREX’s Clinical Trial Management division, now Premier Research. David was a Sr. Clinical Research Scientist at Isis Pharmaceuticals, and later Associate Director of Clinical Development at FeRx in San Diego, California. Prior to joining Oncotherapeutics, he was responsible for operational oversight of all facets of clinical trials for Arena Pharmaceuticals. Oncotherapeutics is a full service Contract Research Organization (CRO) dedicated to the therapeutic oncology area.
With team expertise in phase I-IV clinical trials and pharmacokinetic studies, Oncotherapeutics offers a wide array of services that are custom tailored to each trial. Nationally recognized research oncologists and key opinion leaders in the oncology field oversee senior level clinical research teams for every clinical trial. Oncotherapeutics has successfully conducted a multitude of oncology studies in the areas of multiple myeloma, myelodysplastic syndrome, monoclonal gammopathy of undetermined significance (MGUS), melanoma, non-small cell lung cancer (NSCLC), advanced melanoma, breakthrough cancer pain, other hematologic malignancies, and metastatic bone disease. For more information, please visit www.oncotherapeutics.com or call 310-623-1200.
